Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
16.48%
Operating Margin
0.91%
Net Margin
-3.78%
Efficiency Metrics
Revenue per Expense Ratio
1.01
R&D as % of Revenue
0.09%
Earnings Quality
EBITDA Margin
7.71%
Income Tax Rate
-11,585,400,000.0%
EPS
-1.4900000000
Balance Sheet Analysis
Current Ratio
1.34
Cash Ratio
0.50
Working Capital
$6.56B
Debt to Equity
1.60
Debt to Assets
41.59%
Equity Ratio
26.06%
Cash Flow Analysis
Operating Cash Flow Ratio
4.22%
Free Cash Flow Ratio
-0.29%
CapEx to Revenue
4.51%
Dividends Paid
No dividends paid
Stock Buybacks
$742.46M
Total Shareholder Returns
$742.46M
Cash Position Change
14.11%
Key Takeaways (2023 FY)
Revenue declined by 0.35236112134353%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased R&D investment by 43.88%
Detailed Growth Metrics
Core Performance
Revenue
-0.35%
Net Income
34.37%
EPS
49.32%
Operating Income
0.73%
Operational Efficiency
R&D Expenses
43.88%
SG&A Expenses
14.18%
Operating Cash Flow
109.95%
Free Cash Flow
681.26%
Balance Sheet Health
Assets
-1.01%
Debt
-10.33%
Book Value per Share
2.39%
Inventory
-21.01%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
29.23%
Long Term Trends
3Y Revenue/Share
-19.20%
5Y Revenue/Share
5.93%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%